262 related articles for article (PubMed ID: 16648402)
1. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of four management strategies in the determination and follow-up of atypical squamous cells of undetermined significance.
Hughes AA; Glazner J; Barton P; Shlay JC
Diagn Cytopathol; 2005 Feb; 32(2):125-32. PubMed ID: 15637677
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
5. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
Kim JJ; Wright TC; Goldie SJ
JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
Wright TC
Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
[TBL] [Abstract][Full Text] [Related]
13. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
14. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
15. Significance of atypical repair in liquid-based gynecologic cytology: a follow-up study with molecular analysis for human papillomavirus.
Ng WK; Li AS; Cheung LK
Cancer; 2003 Jun; 99(3):141-8. PubMed ID: 12811854
[TBL] [Abstract][Full Text] [Related]
16. Cytologic diagnosis of atypical squamous cells of undetermined significance in perimenopausal and postmenopausal women: lessons learned from human Papillomavirus DNA testing.
Johnston EI; Logani S
Cancer; 2007 Jun; 111(3):160-5. PubMed ID: 17506090
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
Saraiya M; Irwin KL; Carlin L; Chen X; Jain N; Benard V; Montano DE
Cancer; 2007 Sep; 110(5):1024-32. PubMed ID: 17628488
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL
Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586
[TBL] [Abstract][Full Text] [Related]
19. Hybrid capture as a means of detecting human papillomavirus DNA from liquid-based cytology specimens: a preliminary evaluation.
Callaghan J; Karim S; Mortlock S; Wintert M; Woodward N
Br J Biomed Sci; 2001; 58(3):184-9. PubMed ID: 11575742
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
Goldie SJ; Kim JJ; Wright TC
Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
